Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck

Read MoreHide Full Article

For Immediate Release

Chicago, IL –January 28, 2019 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: J&J (JNJ - Free Report) , Bristol-Myers (BMY - Free Report) , Lilly (LLY - Free Report) AbbVie (ABBV - Free Report) and Merck (MRK - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Pharma Stock Roundup: JNJ, BMY, LLY & More

J&J and Bristol-Myers set the earnings season in motion for the pharma space. Meanwhile, Lilly and AbbVie faced pipeline setbacks with failure of their late-stage studies. Lilly’s confirmatory study to convert soft tissue sarcoma drug Lartruvo’s conditional approval to full approval and AbbVie’s Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints.

Recap of the Week’s Most Important Headlines

Inside J&J & Bristol-Myers’ Q4 Earnings: J&J beat estimates for both earnings and sales in the fourth quarter of 2018. Sales increased 1% from the year-ago quarter to $20.4 billion while earnings per share rose 13.2% to $1.95 per share. Pharmaceutical segment sales rose 5.3% year over year. However, J&J’s sales guidance for 2019 was below expectation.

Bristol-Myers beat estimates for earnings while missing the same for sales. Revenues were up 10% year over year to $6 billion while earnings rose 38% to $94 per share. However, the company announced the voluntary withdrawal of a label expansion application for Opdivo + low-dose Yervoy combination in first-line ling cancer, which pushed its share price down. Opdivo sales were up 33% in the fourth quarter. Bristol-Myers confirmed its 2019 earnings guidance range of $4.10 to $4.20.

Lilly’s Confirmatory Study on Lartruvo Fails: Lilly’s drug Lartruvo, which had won conditional approval two years back, failed to improve survival for patients with advanced soft tissue sarcoma in a late-stage confirmatory study, ANNOUNCE.

The ANNOUNCE study evaluated Lartruvo in combination with doxorubicin, a standard of care chemotherapy compared with doxorubicin alone. The study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population. It was noticed that there was no difference in survival between the study arms for either population. The study thus did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as shown earlier in a phase II study. The clinical benefit achieved earlier had led to an accelerated approval of Lartruvo+doxorubicin by the FDA and conditional marketing authorization by the European Medicines Agency in 2016.

Continued approval was contingent on verification of clinical benefit in a confirmatory study. With ANNOUNCE failing to confirm clinical benefit, Lilly said it will stop promoting Lartruvo while remaining in discussion with global regulators to determine the next steps for the drug.

AbbVie’s Imbruvica Fails in Pancreatic Cancer Study: AbbVie’s late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit.

The RESOLVE study evaluated Imbruvica plus chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents for the treatment of first-line metastatic pancreatic cancer, one of the most aggressive and deadliest forms of cancer. Imbruvica, currently approved for nine cancer indications, has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica’s label into solid tumors and autoimmune diseases.

FDA Accepts Merck’s sNDAs for HIV Medicines: Merck’s supplemental new drug applications (sNDAs) looking for label expansion of its two new HIV drugs — Pifeltro and Delstrigo — was accepted by the FDA. Pifeltro and Delstrigo were approved by the FDA in August for the treatment of adults with no prior antiretroviral treatment experience. The sNDAs are looking to get the HIV drugs approved for use in treatment-experienced adults living with HIV-1 whose virus is suppressed to switch to Pifeltro (in combination with other antiretrovirals) or Delstrigo. The FDA is expected to give its decision on Sep 20. The sNDAs were based on data from the phase III DRIVE-SHIFT study. Data from the study, presented in the past, has shown non-inferior efficacy for those who switched to Delstrigo compared to those who continued on their baseline regimen.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.